Navigation Links
Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
Date:12/1/2008

-- Conference Call Scheduled for Tuesday, December 9 at 11:00 am ET to Discuss Phase 2 Study Results in AML --

SOUTH SAN FRANCISCO, Calif., Dec. 1 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics, today announced new data from its studies of voreloxin in acute myeloid leukemia (AML) will be presented during the 50th American Society of Hematology (ASH) Annual Meeting in San Francisco, California, December 5-9, 2008. Researchers will present updated interim data from the company's ongoing Phase 2 clinical trial of single-agent voreloxin (formerly SNS-595) for elderly patients with newly diagnosed AML and from its Phase 1b/2 study of voreloxin in combination with cytarabine for relapsed/refractory AML. In addition, results from the Phase 1 study of SNS-032, a selective inhibitor of cyclin dependent kinases 2, 7 and 9, in both chronic lymphocytic leukemia and multiple myeloma will be presented. Following are the details on each of these data presentations.

Sunday, December 7, 2008

Viewing: 9:00 a.m. to 8:00 p.m. PT

Presentation Time: 6:00 p.m. to 8:00 p.m. PT

Hall A, MosconeCenter

Abstract #1951

Title: "Phase 2 Study of Voreloxin (Formerly Known as SNS-595) as Single Agent Therapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Preliminary Safety and Clinical Responses (The REVEAL-1 Study)"

Poster Board II-45

Abstract #1955

Title: "Voreloxin (formerly known as SNS-595) in Combination with Cytarabine Demonstrates Preliminary Clinical Responses in a Phase 1 Study in Relapsed/Refractory Acute Myeloid Leukemia"

Pos
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
2. SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
3. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
4. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
5. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
6. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
7. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
8. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
9. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
10. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
11. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... 2014 ... the addition of the  "China Interventional Cardiovascular ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... China impacted by accelerated ... concept, dietary habit, way of working and ...
(Date:10/17/2014)... , Oct. 17, 2014 A victim of medical ... doctor with a history of alcohol abuse, a ... Yes on Prop 46 today, highlighting how Prop 46 will ... alcohol testing. The ad pictures a doctor ... "911-Report To ER."  Proposition 46 will enact the first law ...
(Date:10/17/2014)... 17, 2014  UBM Medica US announces that ... and other clinicians who treat patients with type ... effective use of insulin .  Nearly ... replacement therapy – daily injections of one or ... in the function of pancreatic beta cells. Insulin is ...
Breaking Medicine Technology:China Interventional Cardiovascular Device Industry Report 2014-2017 2China Interventional Cardiovascular Device Industry Report 2014-2017 3Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 2Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 3Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 4Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3
... New Mexico Software, Inc. (OTCBB: NMXC) announced today the ... Revenue for the first quarter ended March 31, ... reported in the same quarter a year ago. Net income ... 2010. New Mexico Software Dick Govatski said, ...
... 16, 2011 HYCOR Biomedical, Inc., a leading manufacturer and ... autoimmune and urinalysis markets, together with owner Linden, LLC, today ... Ph.D., to its Board of Directors as part of its ... welcome Drs. Aggarwal and Koziarz to the HYCOR team and ...
Cached Medicine Technology:New Mexico Software Announces 2011 First Quarter Financial Results 2New Mexico Software Announces 2011 First Quarter Financial Results 3HYCOR Expands Board of Directors to Support Growth in Key Areas 2
(Date:10/20/2014)... With a mere 19 days to November 4, ... fundraising stop at the  Law Offices of Dan ... debate last night with his opponent Gov. Rick Scott, ... seven minutes because Crist had an electric fan underneath ... one word: "weird." , Before touching on his well-known ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 ASCNYC ... organization that helps New Yorkers living with HIV/AIDS ... toward health, housing, recovery and self-sufficiency. Each year, ... the local community through their tireless efforts. , ... Marc Shapses , has been selected as this ...
(Date:10/20/2014)... October 20, 2014 hc1.com today ... secure cloud solution that enables healthcare organizations of ... ultimate healthcare-specific customer relationship management (“CRM”) solution. , ... unique needs of the healthcare industry, the hc1 ... providers and patients by combining healthcare CRM, HIPAA-compliant ...
(Date:10/20/2014)... My Clients Plus ( http://www.MyClientsPlus.com ) today announced ... module enables easy administration and routing of follow-up items ... This application allows users such as Therapists to assign ... item to a specific client, categorize tasks the way ... for follow-ups. It's designed to enable easy access ...
(Date:10/20/2014)... PA (PRWEB) October 20, 2014 ... Matthew Voicheck as Assistant Director of their ... role in managing the innovative turnkey drug sourcing, ... , Matthew brings over 12 years of industry ... joins Myoderm at the peak of their international ...
Breaking Medicine News(10 mins):Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2
... major contributor to heart disease , THURSDAY, April 29 ... the risk of heart disease as much as high ... , Researchers think that by targeting the enzyme, which ... another weapon to fight heart disease. , The enzyme ...
... condition can sometimes require hospitalization, experts point out , ... women who suffered from a severe form of morning ... by it themselves, Norwegian researchers report. , This form ... vomiting beginning before the 22nd week of gestation. In ...
... dogs like Cassidy to romp on all four legs ... Juniper from walking normally. Frostbite damaged the hind legs of ... a wolf trap. , Until a few years ago, there ... ever leading normal lives again. But thanks to advancements in ...
... Concerns about H1N1 flu likely motivated people to get ... (HealthDay News) -- Apparently spurred by concerns about the ... of Americans -- especially children and younger adults -- ... U.S. health officials reported Thursday. , The increases in ...
... Day Twenty-Eight ... on a true story. , , ... April 28, 2010 -- Day Twenty-Eight Films has tapped Ronald Krauss to write and direct the ... her teen pregnancy. , , , , ,Krauss is an award winning writer and director known ...
... Unchecked, the natural or innate immune system can run ... car. Eventually, it will kill the host it is supposed ... how this innate immune system is turned on, but little ... important because the innate immune system is associated with inflammation. ...
Cached Medicine News:Health News:Watch Your Cholesterol, Your Blood Pressure ... and This Enzyme? 2Health News: Severe Morning Sickness Passed From Moms to Daughters 2Health News: Severe Morning Sickness Passed From Moms to Daughters 3Health News:Artificial Legs Now a Reality for Pets 2Health News:Artificial Legs Now a Reality for Pets 3Health News:Record Number of Americans Got Flu Shots, CDC Says 2Health News:Record Number of Americans Got Flu Shots, CDC Says 3Health News:Day Twenty-Eight Seeks Krauss For 'Shelter': Film will Personalize Epidemic of Teen Pregnancy 2Health News:A single protein regulates 2 immune pathways 2
... The Advia 2400 has ... volume (as low as ... consumption (40 L/hour) thus ... optional universal rack handler ...
Iron (Total/Ferene). Storage temp: 15 - 30 C. Linearity: 0 - 500 ug/dl. Expected values: from males 60 - 160 ug/dl, from females 43 - 140 ug/dl. Available with Calibrator and Number of test are 120....
Iron UIBC (UIBC Buffer + Color + Std.). An Automated analyzer test kits....
For the quantitative determination of Iron and IBC in serum. Colorimetric method utilizing ferrozine. Endpoint procedure measured at 560 nm. Linearity: 500 ug/dl....
Medicine Products: